Risa Wong, MD, reviews the standard treatment options for patients with metastatic urothelial cancer.
Risa Wong, MD, hematology/oncology fellow at the University of Washington, reviews the standard treatment options for patients with metastatic urothelial cancer (mUC).
Patients with mUC who are defined as fit, are treated with first-line platinum-based combination chemotherapy as standard of care, explain Wong. In the past, after patients subsequently progressed, there were very limited options for subsequent therapy, and providers ended up retreating many of these patients with chemotherapy, either rechallenging them with a platinum-based regimen or switching to a nonplatinum-based chemotherapy regimen.
In recent years, there have been many advances in the treatment landscape and these patients can now receive immune checkpoint inhibitors.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More